£7.0M
The financing round was led by Soulmates Ventures with backing from several new and existing investors.
.png)
Antiverse
Antiverse develops AI-designed therapeutic antibodies for challenging disease targets using computational platforms and in-house laboratories.
£14.4MTotal raised
Antiverse is a techbio company that uses artificial intelligence and in-house laboratories to design therapeutic antibodies for complex disease targets. Headquartered in Cardiff, the firm develops treatments for conditions involving challenging molecular structures.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Antiverse's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
Murat Tunaboylu
Co-Founder and CEO
Murat is the chief executive officer at Antiverse. He previously held roles at Thermo Fisher Scientific, Deep Science Ventures, and Singer Instrument Co Ltd.
LinkedInInvestors
- £7.0M
- £3.5M
- £2.5M
- £1.4M
Funding history
£3.5M
The latest investment brings total equity financing to £7.2m and will support clinical progression of internal assets.
£2.5M
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
£1.4M
The seed round was supported by a syndicate of investors including the Development Bank of Wales and the UKI2S Innovate Accelerator to fund platform development and laboratory expansion.